Prostate Cancer   

Questions discussed in this category


Only the mCRPC population was included in the Fizazi et al. study, but the FDA approval is for prevention of skeletal related events from any solid tu...

Which patients specifically benefit from both mpMRI and PET-PSMA?

How would it change your risk group or management? Does Decipher help further inform treatment?

I have a pair of patients with MRI+ and biopsy+ disease who have staging PSMA PET/CT that do not show disease within the prostate (or anywhere else).&...

When (if ever) would you consider immune checkpoint inhibitor up front? Would you be less inclined to offer triple drug therapy? (Some thought that ta...

Given the FDA approvals for PARP inhibitors and combinations in mCRPC, when do you obtain NGS for mCRPC? Do you have a preferred assay?

If baseline testosterone is at castrate levels (e.g. <50), would you consider patient to have castrate-resistant disease?

In particular, in the modern era of multi-parametric prostate MRI and PSMA-PET, certain findings such as EPE, SVI, or pelvic lymphadenopathy may be no...

In the setting of EBRT alone, a "FLAME"-style boost may increase bPFS. Does anyone have experience with increasing the EBRT dose in combination EBRT+L...

He cannot sense bladder fullness but has no incontinence. Intermittently he urinates by increasing intra-abdominal pressure resulting in a good stream...

For example do you use Prolaris, or other genetic tests to guide ADT decision making? 

Assume recurrence is biopsy proven. Would you ever consider focal vs whole gland brachytherapy? 

Patients in their later 40s with favorable intermediate-risk prostate cancer s/p 7000cGy/28 EBRT only.

24 months ADT + abiraterone + definitive RT is indicated for cN1 disease but not for pN1 disease per NCCN. Can the data be extrapolated to this popula...

Notably, the patient presented with renal failure due to ureteral obstruction and hydronephrosis, receives hemodialysis, and has limited systemic opti...

For example: radiation fractionation schedule, modality (proton, MRI linac, cyberknife, etc), risk categorization, prostate size, history of IBS, hist...

How would you sequence therapy, and what dose and volumes would you use for radiation? Prostate cancer is localized, Gleason 4+3, PSA 65.

Pretreatment PSA 25.3 with Gleason 4+3=7 and MRI suspicious for ECE. Eight months after pelvic nodal and prostate XRT to 79 Gy, PSA is 5.02 (down from...

A recent NCBD analysis (Rusthoven et al., PMID 27325855) suggests that the addition of prostate RT significantly improves survival compared to AD...

Specifically if metastatic risk estimate approached the failure rate in control arm of STAMPEDE for high-risk non-metastatic disease (69% MFS at 6 yea...

Would you recommend elective nodal radiation and sequential boost to the node? What dose? Would you recommend treatment similar to OLIGOPELVIS-GETUG P...

There is a recent publication that nicely summarizes the molecular/genetic tests for prostate cancer (Ross et al., PMID 26123120). What should be done...

What imaging modality do you use (conventional, PSMA PET, etc.)? When do you image (ex: a PSA threshold or PSADT)?

Is there an extent of nodal involvement in prostate cancer above which you would not offer definitive XRT? With PSMA/PET we see some patients with inc...

Do you wait for radiographic progression? What is your preferred imaging modality for re-staging?

If a patient who has undergone radical prostatectomy many years previously presents with biochemical failure and is found to have a nodule in the pros...

Current NCCN guidelines recommended not combining relugolix with these agents until more data is available.  Any drug interaction concerns or ot...

Specifically, in the TZ and PZ? What references do use for prostate nodule boost as done in FLAME trial?  Hypointensities are contoured on T2W M...

How high would you try to boost those involved nodes if they are in a favorable location with respect to his rectum and small bowel? 

Would you treat with ADT if no metastatic disease? Does absolute PSA (e.g. PSA<2) inform decision?

Additional imaging of the potential lesions, biopsy or assume negative given normal PSMA PET/CT. 

Or would you proceed with cabazitaxel or other therapy? Initial chemo-hormonal therapy was ADT + Docetaxel x6 cycles.Docetaxel rechallenge at time of ...

Do you find the ibPFS endpoint sufficient to change practice for any or all patients, or will you await OS or other data/trials?

Do you allow this finding to change your management, or ignore it, as the "lesion" was not malignant?

If yes, would you directly add olaparib at progression on abiraterone vs waiting to use abi/olaparib at a later line of therapy?

Would you offer adjuvant radiation? (Dose? Target?) vs Salvage? Would you add ADT? Would you add abiraterone? Would the number of lymph nodes involv...

Patient has ED unresponsive to cialis/viagra; would you recommend testosterone replacement therapy?

At what PSA would you become suspicious for biochemical recurrence and pursue restaging? Is there a threshold value? What imaging modality would you ...

Would you use it for initial staging or at time of biochemical recurrence?

Would you consider boosting the nodes?  What dose?  Would this change your recommendation for length of ADT?  

Would you consider chemotherapy, androgen blockade or triple therapy (chemo and AR targeting)?

Are there clinical features (post-op PSA, Decipher score, pN+, pT3, etc) that would inform your decision?

Given GU003 presented at ASTRO 2021- how does this impact your recommendations for adjuvant and salvage prostate RT?

Do you worry about false negatives on PET, CT, MRI if ADT is started before the scan? Scheduling scans can sometimes book 2-4 weeks out. 

Per lutathera information, a patient who had previous treatment for describes an estimated radiation absorbed dose of 12.8 Gy to the bladder. Would yo...

Is there a role of EBRT to the prostate with extended fields to cover the retroperitoneal nodes plus ADT (definitive therapy) or would you treat as ca...

PSA rose from 25 to 30 ng/mL over 6 months on darolutamide for M0 CRPC, prompting scans which showed oligometastatic disease to bone, not amenable to ...

GS 4+4. PSA low (1-2). CT and bone scan negative for lymphadenopathy or metastatic disease.  Prostate MRI pending. 

Would you recommend surgery first or neoadjuvant therapy such as concurrent cisplatin/RT or another regimen?

Did you change your practice given the SRE results in the control arm of EORTC 1333 at ASCO 2021? When using bisphosphonates or denosumab, what dosin...

For the purpose of this question, please assume an initially undetectable post-prostatectomy PSA, no presence of positive margins, extracapsular exten...

Are there certain situations where a hydrogel spacer is most useful based on treatment modality (SBRT, protons, brachy, etc) or other factors?

Do prior treatments for mHSPC change your thinking on whether or not to use sipuleucel-T?

Specifically, would you offer salvage radiation to a patient who underwent a prostatectomy with PLND and had a post-op PSA of 12 with pathology reveal...

What clinical scenario(s) do you find results to be the most beneficial?

Assuming patient received appropriate local therapy for brain metastases, which agent would you use?

What is the time window in which you would consider adding AR targeted therapy? Is there a time frame in which you would NOT consider introducing sin...

Is there an optimal strategy to minimize unnecesary steroid use?For example, pre-treatment dexamethasone or 3 day dexamethasone? Prednisone only conti...

Is there data and FDA approval for this indication? What about for nodal failure after radiation? 

What dose constraint would you use for the neobladder? Small bowel constraint of 54Gy? Or would you recommend observation or ADT alone or low dose RT ...

How would a much higher risk cancer affect decision making? How would you treat him? 

Abstract 5014 at ASCO annual meeting 2019 showed superiority of PSMA-PET imaging over fluciclovine-PET imaging.  Are you utilizing these speciali...

Do you offer EPO and TPO support? Do you modify your systemic therapy up front or after subsequent cycles?

In the SPARTAN trial, median PSA at study entry was ~ 7. Does the MFS benefit extend to patients with low PSA(< 2 or < 1)?

For instance, if the fluclicovine scan shows a few small avid nodes not only in the pelvis but extending to the paraaortic region, would you treat the...

Will your recommendation change if there is suspicious/confirmed locally recurrent nodule in the prostate bed?

In a patient with a prior response to ADT and progression on taxane and platinum chemotherapy, would you consider AR directed therapy?

Per the ALSYMPCA study, they excluded patients with > 3cm lymphadenopathy. Patient is currently on enzalutamide and leuprolide and refuses docetaxe...

Does the STAMPEDE trial, showing a survival benefit with the addition of docetaxel to standard treatment, change the standard of care for high risk, n...

Is there a benefit to one fractionation schedule v. the other?

Treatment for small cell/neuroendocrine prostate is extrapolated from data on small cell lung cancer. It now appears that Carboplatin + Etoposide + At...

Are you directed by symptoms, PSA changes or do you have a standard schedule regardless of those factors?

Abstract LBA5_PR ‘Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCA): survival results from S...

Prospective International Randomized Phase II Study of Low-Dose Abiteraterone with Food versus Standard Dose Abiraterone In Castration-Resistant Prost...

Is there a dose response relationship, as suggested in the phase I MSKCC dose escalation study presented at ASTRO 2017?

For which patients would you consider addition of apalutamide or enzalutamide? How do you decide between the 2 drugs?

NCCN recommends to change therapy or maintain current therapy in this setting without further clarification. What thresholds would cause a change in t...

Based on the updated results of the PCS IV trial is 18 months of ADT the new standard of care for men with high-risk prostate cancer treated with...

Would you initiate abiraterone or enzalutamide for the rising PSA or wait until the patient is symptomatic or has a new site of metastasis?

In the case of patients many years out from RP who have a slowly rising PSA, do you offer salvage RT while the PSA is still very low or follow the PSA...

In patients with new bone pain and without any evidence of bone metastases receiving GnRH agonists, how do you manage pain symptoms?

With biopsy-proven, negative systemic restaging disease, what dose and fractionation is appropriate if treating with IMRT? Should ADT generally b...

Would you consider this an indication to treat lymph nodes, if you would typically not do so?

Is there an upper limit to offer definitive RT? Is it possible to have a PSA of 100-500 and still have only local disease?

Is there a role for salvage LN dissection or salvage RT to the node? And is there a role for systemic therapy (ADT or chemotherapy) in addition? If yo...

Should the workup change with the PSA level (for example, >2 vs <2 ng/ml post-op PSA)?  Is there a PSA level for which salvage radiotherapy...

Two retrospective studies from Stanford showed that patients who received ADT had an increased risk of dementia and Alzheimer's. Is this finding ...

Do you use a PSA threshold, PSA doubling time, or only evidence of metastatic disease to trigger ADT? For those without rapid doubling time, do you ev...

In the recent 10 year update of the ARO (adjuvant pelvic RT versus observation) trial, their definition of PSA failure was 2 successive rise...

Would a specific Gleason score, age, pathological feature, or PSA be an indication for covering the pelvic nodes? Would giving concurrent ADT affect y...

Given recent advancements in the understanding of biological differences in prostate cancer patients of African vs. other ancestry, does your manageme...

Does PSADT play a factor in your decision-making? If so, how specifically?  I've tended to wait until the PSA is 10-15, re-image, and then begin...

If so, how do you sequence this with other therapies?  In addition, in the absence of an effect on radiographic PFS or serum PSA, how do you asse...

In situations where there is a significant risk of either local or nodal persistence/recurrence post prostatectomy with a rising PSA, or nodal involve...

A recent systematic review suggested that disease progression owing to a testosterone "flare" may not be a real phenomenon: http://www.ncbi.nlm.nih.go...

The role of adjuvant docetaxel with ADT following RT for high risk disease has been previously elucidated by RTOG 0521.  Following prostatectomy,...

At the ASCO 2016 annual meeting, results of the PRINCE trial were reported. A strategy of intermittent docetaxel was found to be non-inferior to conti...

 In a patient with node positive disease, treated definitively with radiation, should continuous or intermittent ADT be administered? If a patien...

Typically radium-223 is reserved for men with symptomatic bone disease after failure of multiple other therapies.  Is there a population of men w...

Guidelines dont seem to account for this possibility. Could it just be normal prostate tissue growing back that is leading to PSA, why just assume it ...

In starting prostate SBRT at an instutution, what are issues with the treatment that one should pay special attention to?

On what other factors should be considered in making a treatment recommendation for salvage radiation therapy?

What factors should be considered with offering SBRT to oligometastatic bone disease in prostate cancer patients? Should this been done off of a proto...

With ultra-sensitive PSA, it's unclear to me whether a doubling from 0.01 to 0.02 or 0.02 to 0.04 is significant. Is there a certain value that you wo...

If a patient is deemed high risk enough to require hormones with RT in the salvage setting, how long would you maintain them on ADT? Would you extrapo...

When counseling patients with organ-confined prostate cancer, what rates of impotence, incontinence, rectal toxicity, and urethral stricture shou...

The optimal timing of post-prostatectomy RT in high-risk patients is debatable and currently the question of prospective randomized trials; however, g...

Do you use a particular cut-off? For example, someone in their 40's?

The patient has a positive bone scan (2 lesions), grade 4+5=9/10 prostate, and cancer cannot urinate without a catheter.

More specifically, which cardiac risk factors do you look for? Diabetes? Previous MI? Dyslipidemia? Peripheral vascular disease? CHF?

In general how do you counsel patients with high risk prostate cancer when choosing radiation verse prostatectomy? What numbers do you quote for ...

This is a patient who would have been an appropriate candidate for radiation upfront, but was managed with androgen deprivation therapy instead. On th...

Sometimes the scans don’t line up well because of differences in rectal and bladder fullness- any tips to optimize the fusion?

I ask this because I am seeing more and more patients who have had surgery despite presenting with high risk disease.

I know many do not treat the pelvis at all, but for those who do, what criteria do you use? Risk? Gleason? PSA? T stage?

And should special precautions be taken (such as dose reduction, prophylactic symptom management, etc)?


Papers discussed in this category


International journal of radiation oncology, biology, physics, 2005-04-01

Int J Radiat Oncol Biol Phys, 2005 Sep 1

International journal of radiation oncology, biology, physics, 2004-06-01

International journal of radiation oncology, biology, physics, 2007-08-01

International journal of radiation oncology, biology, physics, 2014-04-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01

Int. J. Radiat. Oncol. Biol. Phys., 2012-12-01

European urology, 2013-12

CA Cancer J Clin, 2010 May-Jun

J Natl Cancer Inst, 2010 Jan 6

BJU international, 2014-12

JAMA, 2011-12-07

Cancer, 2013 May 15

International journal of radiation oncology, biology, physics, 2010-11-01

American journal of clinical oncology, 2016-02

Radiother Oncol, 2013-01-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-03-20

Eur. Urol., 2009-05-01

The American journal of surgical pathology, 2005-09

The New England journal of medicine, 2012-07-19

BMJ, 2014-01-08

International journal of radiation oncology, biology, physics, 2012-05-01

International journal of radiation oncology, biology, physics, 2012-02-01

N. Engl. J. Med., 2009-06-11

JAMA, 2006-11-15

Practical radiation oncology, 2013

N Engl J Med, 2008 Mar 20

The Journal of urology, 2011-09

Practical radiation oncology, 2013

Urologic oncology, 2014-04

BJU international, 2014-03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-03-10

J. Urol., 1998-01-01

Eur. Urol., 2014-03-01

BJU international, 2015-10

The New England journal of medicine, 2011-07-14

International journal of radiation oncology, biology, physics, 2010-04

JAMA, 2015

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-06-20

The Journal of urology, 2012-01

Cancers, 2022 Jan 29

International journal of radiation oncology, biology, physics, 2013-03-15

Cancer, 2014-06-15

Cancer, 2006 Jun 15

International journal of radiation oncology, biology, physics, 2003-03-15

Urology, 2008-11

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-04-10

Lancet, 2016 Mar 19

Eur. Urol.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-05-15

American journal of clinical oncology, 2014-06

International journal of radiation oncology, biology, physics, 2011-07-15

International journal of radiation oncology, biology, physics, 2010-07-15

Frontiers in oncology, 2011

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-09-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999-04

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-20

The New England journal of medicine, 2017-02-02

JAMA Oncol, 2017-10-01

Seminars in radiation oncology, 2013-07

Eur Urol, 2015 Jul 16

BJU Int, 2009 Feb

European urology, 2014-06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-05-20

The New England journal of medicine, 2013-07-18

JAMA Oncol, 2020 Aug 27

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-10

European urology, 2011-04

Urology, 2001-11

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-01-20

The New England journal of medicine, 2004-10-07

JAMA oncology, 2016-11-01

J. Nucl. Med., 2015 Jun 25

Int. J. Radiat. Oncol. Biol. Phys., 2015 Apr 23

Brachytherapy, 2020 Apr 21

Int. J. Radiat. Oncol. Biol. Phys., 2020 Jan 24

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-04-01

Lancet Oncol., 2010-02-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-03-20

The Journal of urology, 2005-08

Mol Clin Oncol, 2015 May 04

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-12-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-10

The Journal of urology, 1999-07

Annals of oncology : official journal of the European Society for Medical Oncology, 2009-03

Mayo Clin Proc, 2004 Oct

JNCI Cancer Spectr, 2019 Oct 21

N Engl J Med, 1994 Aug 11

The New England journal of medicine, 2018-05-03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-08-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-06-20

The Journal of urology, 2002-09

Clinical cancer research : an official journal of the American Association for Cancer Research, 2009-01-15

Nature, 2005-12-08

J Clin Oncol, 1999 Jul

Lancet, 2015 Jan 3

The New England journal of medicine, 2001-12-06

Lancet, 2001-09-22

Breast Cancer Res. Treat., 2010-02-01

The Journal of urology, 1982-06

Cancer research, 2000-04-15

J. Clin. Oncol., 2009-04-01

Oncol. Rep., 2015-12-01

Nat Commun, 2015-04-01

PLoS ONE, 2016-01-01

J. Urol., 2002-04-01

Lancet Oncol., 2015 Sep 09

European urology, 2018-02

Lancet, 2018 Oct 18

The New England journal of medicine, 2015-08-20

JAMA, 2008-06-18

International journal of radiation oncology, biology, physics, 2007-11-01

The Lancet. Oncology, 2006-06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-02-20

JAMA oncology, 2016-04

JAMA oncology, 2017-01-01

JCO Precision Oncology, 2017 May 31

The New England journal of medicine, 2016-08-04

NEJM Evidence, 2022 Jun 3

The New England journal of medicine, 2018-04-12

The New England journal of medicine, 2018-06-28

Int J Radiat Oncol Biol Phys, 2012 Jul 15

International journal of radiation oncology, biology, physics, 2011-06-01

Lancet, 2008 Dec 16

Lancet, 2011-12-17

Urology, 2017-04

Eur Urol Oncol, 2020 May 22

Int J Radiat Oncol Biol Phys, 1986 Mar

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-10

JAMA Oncol,

J Urol,

Frontiers in oncology, 2017

International journal of radiation oncology, biology, physics, 2008-09-01

European urology, 2018-07

International journal of radiation oncology, biology, physics, 2008-04-01

International journal of radiation oncology, biology, physics, 2014-07-01

International journal of radiation oncology, biology, physics, 2016-07-01

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2013-11

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-05-20

Frontiers of radiation therapy and oncology, 2011

Semin Radiat Oncol, 2016 Aug 31

Urology, 2013-06

International journal of radiation oncology, biology, physics, 2018-06-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-08-20

N. Engl. J. Med., 2019 Jun 02

J. Clin. Oncol., 2015 May 26

J. Clin. Oncol.,

Nat Rev Urol, 2014 Apr

Clinical cancer research : an official journal of the American Association for Cancer Research, 2013-07-01

International journal of radiation oncology, biology, physics, 2012-04-01

Brachytherapy, 2016

N Engl J Med, 2010 Jul 29

N. Engl. J. Med., 2017-07-27

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10

Clinical cancer research : an official journal of the American Association for Cancer Research, 2016-03-15

Prostate Int,

Practical radiation oncology, 2018

Practical radiation oncology, 2018

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10

Nat Rev Urol, 2017 Dec 12

Journal of contemporary brachytherapy, 2016-10

International journal of radiation oncology, biology, physics, 2012-07-01

Radiother Oncol, 2009 Apr

Lancet, 2021 Dec 23

The New England journal of medicine, 2017-07-27

Ann. Oncol.,

The Lancet. Oncology, 2013-08

Eur Urol, 2017 Oct 23

J Clin Oncol, 2017 Jul 28

N. Engl. J. Med., 2019 May 31

J. Clin. Oncol., 2019 Jul 22

Lancet Oncol, 2019 Apr 12

Semin Radiat Oncol, 2004-01-01

Practical radiation oncology, 2017

AJR. American journal of roentgenology, 2019-10

JAMA oncology, 2019-06-01

Clin Nucl Med,

The Lancet. Oncology, 2019-03

JAMA Oncol,

European urology, 2018-08

N. Engl. J. Med., 2019 Sep 30

Lancet,

Eur. Urol., 2018 Jul 03

Lancet, 2019 Apr 11

J. Clin. Oncol., 2017 Dec 14

Eur. Urol., 2019 Jul 19

J Thorac Oncol. , 2019 Oct 17

Cancer, 2020 Feb 19

Clin Genitourin Cancer, 2019 Mar 13

N. Engl. J. Med., 2020 May 29

Clinical cancer research : an official journal of the American Association for Cancer Research, 2012-12-15

,

BMC Cancer, 2014 Sep 15

JAMA Oncol,

Eur Urol, 2019 Feb 28

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-02-01

Urology, 2001-08

Lancet Oncol., 2016-06-01

JAMA Oncol, 2020 Mar 26

Lancet, 2020 Sep 28

Lancet Oncol,

Lancet Oncol,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01

JAMA Oncol, 2021 Feb 18

The New England journal of medicine, 2012-09-06

Radiother Oncol, 2020 Apr 01

The Lancet. Oncology, 2012-02

International journal of radiation oncology, biology, physics, 2016-11-01

Cancer, 2018-07-15

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-02-01

Oncologist, 2020 Dec 03

Urology, 2000-11-01

Abdom Radiol (NY), 2019 Aug 29

Lancet, 2021 May 07

N. Engl. J. Med., 2016-10-13

J Urol, 2020 Apr 13

Eur J Nucl Med Mol Imaging, 2020 Aug 12

J Urol,

Lancet Oncol, 2010 Oct 07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-04-10

Prostate Cancer Prostatic Dis, 2020 May 13

The Lancet. Oncology, 2018-11

The Prostate, 2019-09

J Urol, 2020 Dec 28

Lancet Oncol, 2020 Mar 27

Clinical genitourinary cancer, 2018-06

Cancer treatment and research communications, 2019

Prostate Cancer Prostatic Dis, 2020 Feb 28

Cancer, 2019 Dec 1

Nat Rev Urol, 2021 Apr 06

Eur Urol, 2020 Dec 03

J Clin Oncol, 2021 Jan 26

Pancreas, 2010-08

American journal of clinical and experimental urology, 2014

The Prostate. Supplement, 1998

The Prostate, 2001 May 15

Clinical nuclear medicine, 2017 Jan

The New England journal of medicine, 2019-03-28

Clin Cancer Res, 2019 Sep 11

Lancet Oncol, 2019 Oct 16

JAMA Oncol,

J Urol, 2021 Feb 26

Journal of the National Comprehensive Cancer Network : JNCCN, 2014-05

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-02-01

International journal of radiation oncology, biology, physics, 2015-06-01

International journal of radiation oncology, biology, physics, 2017-06-01

Proceedings of the National Academy of Sciences of the United States of America, 2011-06-07

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017-01

European journal of nuclear medicine and molecular imaging, 2018-11

European urology oncology, 2018-05

J Nucl Med, 2021 Dec 16

J Nucl Med, 2018 Dec 14

Eur J Nucl Med Mol Imaging, 2019 Nov 15

Eur J Nucl Med Mol Imaging, 2019 Dec 26

JAMA Oncol,

J Urol, 2021 Feb 03

J Nucl Med, 2020 Jan 10

Clin Cancer Res, 2021 Feb 23

N Engl J Med, 2020 Apr 28

Prostate cancer and prostatic diseases, 2018-04

JCO Precis Oncol, 2020

Lancet Oncol, 2019 Sep 09

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01

BJU international, 2014-12

The Journal of urology, 2002-09

Lancet, 2020 Sep 28

BMC cancer, 2019-06-13

J Clin Oncol, 2022 Mar 15

N Engl J Med, 2022 Feb 17

Am J Clin Oncol,

Prostate, 2022 Jun 08

Br J Cancer, 2008 Feb 12

Lancet,

Eur Urol, 2015 Dec 17

BJU Int, 2016 Nov 12

International journal of radiation oncology, biology, physics, 2006-07-15

J Nucl Med, 2021 Jun 24

Oncotarget, 2017 Feb 25

Practical radiation oncology, 2017

Eur Urol, 2020 Jun 09

Urologic oncology, 2017-04

Radiology, 2019-03

J Clin Oncol, 2014 Dec 15

BJU Int, 2020 Feb 12

JAMA Oncol,

BJU Int, 2022 Apr 03

Int J Radiat Oncol Biol Phys, 2020 Sep 11

Lancet Oncol, 2022 Jan 17

Prostate Int, 2019 Feb 22

J Urol, 2019 Sep 06

Lancet,

AJR Am J Roentgenol, 2022 Jun 29

Eur Radiol, 2022 Aug 08

Urology,

Clin Nucl Med,

Skeletal Radiol, 2014 May 20

Eur J Nucl Med Mol Imaging,

European urology, 2019-09

J Clin Oncol, 2021 Jan 20

Radiother Oncol, 2018 May 03

Int J Radiat Oncol Biol Phys, 2016 Apr 21

AJR Am J Roentgenol, 2020 Sep 02

Radiology, 2020 Apr 21

International journal of radiation oncology, biology, physics, 2019-06-01

Eur Urol, 2021 Apr 03

International journal of radiation oncology, biology, physics, 1998-03-01

Front Oncol, 2022 Jun 07

Eur Urol, 2022 Jul 27

Lancet Oncol, 2013 Jan 04

Lancet Oncol,

Radiother Oncol, 2020 Oct 07

Int J Radiat Oncol Biol Phys, 2015 Dec 23

Int. J. Radiat. Oncol. Biol. Phys., 2017-06-01

Radiother Oncol, 2012 Feb 16

AJR Am J Roentgenol, 2021 Jan 21

Lancet Oncol, 2021 Jan 18

Prostate Cancer Prostatic Dis, 2021 Feb 10

Prostate Cancer Prostatic Dis, 2022 Mar 15

Eur Urol, 2021 Jul 08

Eur Urol Focus, 2021 Mar

Adv Radiat Oncol, 2022 Jul 28

J Urol, 2019 01

International journal of radiation oncology, biology, physics, 2010-06-01

International journal of radiation oncology, biology, physics, 2012-01-01

Urology, 2021 Oct 06

Eur Urol Oncol, 2020 Aug 15

JAMA Netw Open, 2021 Jul 01

Adv Urol, 2011 Oct 16

Eur Urol, 2009 Dec 18

Practical radiation oncology, 2015

JAMA, 2005-09-14

JAMA oncology, 2018-06-14

Int J Radiat Oncol Biol Phys, 2021 Nov 03

Eur Urol, 2021 Dec 23

Int J Radiat Oncol Biol Phys, 2000 Sep 01

Radiother Oncol, 2021 Feb 13

J Clin Oncol, 2023 Apr 27

Front Oncol, 2022 Mar 29

Brachytherapy, 2022 May 04

Pract Radiat Oncol, 2023 Jul 11

Nature reviews. Urology, 2018-04

Pract Radiat Oncol, 2021 May 30

Scandinavian journal of urology and nephrology, 2004

BJU international, 2005-10

Andrologia, 2017-02

Current opinion in urology, 2007 Nov

N Engl J Med, 2021 Jun 23

Lancet, 2019 Jun 18

Int J Radiat Oncol Biol Phys, 2015 Jul 15

J Clin Oncol, 2019 Dec 12

J Clin Oncol, 2021 Jan 10

J. Clin. Oncol., 2016-05-20

Lancet Oncol., 2018 Dec 19

Lancet Oncol, 2015 Feb 19

Eur J Cancer, 2020 Dec 03

Pract Radiat Oncol, 2022 Mar-Apr

Prostate, 2020 Feb

BJUI Compass, 2021 Jan 05

Lancet, 2022 Apr 08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10

Eur Urol Oncol, 2022 May 20

J Clin Oncol, 2021 Dec 20

Int J Radiat Oncol Biol Phys, 2023 May 02

J Clin Oncol, 2023 Mar 23

The Lancet. Oncology, 2018-02

Lancet Oncol, 2019 Dec

The Lancet. Oncology, 2019 Sep 29

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021 Nov 10

Annals of oncology : official journal of the European Society for Medical Oncology, 2023 Jul 01

Lancet (London, England), 2023 Jun 04

Eur Urol, 2018 Sep 25

Eur Urol, 2015 May 21

JAMA oncology, 2023 Jun 01

International journal of radiation oncology, biology, physics, 2019-08-01

Lancet, 2021 Feb 11

Eur J Nucl Med Mol Imaging, 2023 Jul 05

BJU Int, 2021 Dec 13

J Urol, 2021 Jan 27

Eur Urol, 2020 Jan 08

Lancet Oncol, 2019 Sep 17

Lancet Oncol, 2021 Feb

The Lancet. Oncology, 2022 Sep 13

Radiother Oncol, 2018 Jan 11

Brachytherapy, 2022 Apr 06

International journal of radiation oncology, biology, physics, 2022 Dec 15

The Lancet. Oncology, 2014-05

The New England journal of medicine, 2023 Oct 19

Health and quality of life outcomes, 2020 May 12

European urology, 2015 Feb 14

International journal of cancer, 2022 May 16

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022 Oct 27

The Lancet. Oncology, 2023 Sep 12

Future oncology (London, England), 2023 Oct 26

Cancer medicine, 2022 Jul 24

European urology, 2022 Apr 18

The New England journal of medicine, 2018-05-10

The New England journal of medicine, 2020 Mar 05

JAMA oncology, 2023 Mar 01

Int J Radiat Oncol Biol Phys, 2019 Oct 17

International journal of radiation oncology, biology, physics, 2024 Feb 28